GlassScriptPhysician profile
Yelena E Kier
NPI 1659532034
$5,718.04
in general payments reported to CMS, 2019-2025
8 companies · $5,131 in 2025
The $5,131 reported for 2025 was more than what 82% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $22.99 · 2023: $287 · 2024: $277 · 2025: $5,131.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,960 · Food and Beverage: $571 · Education: $164.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,960.00 |
| Food and Beverage | $571.48 |
| Education | $163.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stemline Therapeutics INC. | $5,065.84 | 2024-2025 | Orserdu |
| Inari Medical, INC. | $317.25 | 2023-2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Gilead Sciences, INC. | $265.04 | 2021-2025 | Trodelvy |
| Astrazeneca Pharmaceuticals LP | $23.10 | 2025 | |
| Janssen Scientific Affairs, LLC | $20.25 | 2025 | Pipeline |
| Amgen INC. | $15.49 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $11.07 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yelena Kier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.